Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. Cizzle has converted a memorandum of understanding (MoU) with partners in China into a full strategic alliance for the development and commercialisation of its lung cancer test in China.
If you'd like to be introduced to the team at Cizzle Biotechnology, get in touch.Request a meeting